Cost-Effectiveness of Adjuvant Alectinib Versus Chemotherapy for Patients with Resectable, ALK-positive Non-small Cell Lung Cancer in Canada
Our analysis suggests that adjuvant alectinib is dominant (i.e., more effective and less costly) to platinum-based chemotherapy in Canadian patients with resected ALK-positive NSCLC. Together with the DFS benefit seen in ALINA, this analysis supports adjuvant alectinib as an important new treatment strategy.
Authors
- Nick Jovanoski
- J Turki
- Quincy S. Chu (ORCID: https://orcid.org/0000-0003-4814-3126)
- Sarah Vaselenak (ORCID: https://orcid.org/0000-0002-6240-9923)
- Alexandra M. Hogan
Institutions
- Roche (Switzerland) (CH)
- University of Alberta (CA)
- Roche (Canada) (CA)
Publication Details
- Journal
- PharmacoEconomics
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1007/s40273-025-01488-x
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- F. Hoffmann-La Roche